Kidney Week

Abstract: PO0974

Cardiovascular Disease and Medication Use by CKD Risk Groups in People with Type 2 Diabetes: A Post Hoc Analysis from CAPTURE

Session Information

• Diabetic Kidney Disease: Clinical - 1
  October 22, 2020 | Location: On-Demand
  Abstract Time: 10:00 AM - 12:00 PM

Category: Diabetic Kidney Disease

• 602 Diabetic Kidney Disease: Clinical

Authors

• Russo, Giuseppina, University Hospital, Messina, Messina, Italy

Giuseppina Russo,

• Alguwaihes, Abdullah, King Saud University, King Saud University Medical City, Riyadh, Saudi Arabia

Abdullah Alguwaihes,

• Bayram, Fahri, Erciyes University, Kayseri, Kayseri, Turkey

Fahri Bayram,

• Darmon, Patrice, Hôpital de la Conception, Marseille, Provence-Alpes-Côte d'Azu, France

Patrice Darmon,

• Davis, Timothy, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia

Timothy Davis,

• Eriksen, Kirsten Thorup, Novo Nordisk A/S, Søborg, Denmark

Kirsten Thorup Eriksen,

• Hong, Tian-Pei, Peking University Third Hospital, Beijing, China

Tian-Pei Hong,

• Kaltoft, Margit Staum, Novo Nordisk A/S, Søborg, Denmark

Margit Staum Kaltoft,

• Lengyel, Csaba, University of Szeged, Szeged, Hungary

Csaba Lengyel,

• Arenas Leon, Jose Luis, Centro de Atención e Investigación Cardiovascular del Potosí, San Luis Potosi, Mexico

Jose Luis Arenas Leon,

• Mosenzon, Ofri, Hadassah Medical Center, Diabetes Unit, Hebrew University, Jerusalem, Israel

Ofri Mosenzon,

• Rhee, Nicolai, Novo Nordisk Healthcare A/G, Zurich, Switzerland

Nicolai Rhee,

• Shirabe, Shinichiro, H. E. C Science Clinic, Yokohama, Japan

Shinichiro Shirabe,

• Urbancova, Katerina, Diabetologická Interní Ambulance s.r.o, Ostrava, Czechia

Katerina Urbancova,

• Vencio, Sergio, Instituto de Ciencias Farmaceuticas, Aparecida de Goiania, Goiás, Brazil

Sergio Vencio,

• Dieuzeide, Guillermo, Centro de Atención Integral en Diabetes, Buenos Aires, Argentina

Guillermo Dieuzeide,

Background

The CAPTURE study estimated the contemporary (2019) prevalence of cardiovascular disease (CVD) in people with type 2 diabetes across 13 countries. This post hoc analysis describes the occurrence of CVD and medication use by chronic kidney disease (CKD) risk groups.

Methods

CAPTURE was a multinational, cross-sectional, non-interventional study conducted between December 2018 and September 2019. Data on CVD diagnoses, estimated glomerular filtration rate (eGFR), urine albumin level and glucose-lowering agents (GLA)/CVD medication use was collected during routine visits. Participants were categorized by CKD risk by eGFR and urine albumin thresholds according to the KDIGO classification.

Results

Of 9823 participants, 7923 (81%) had eGFR data, 6482 (66%) had urine albumin creatinine ratio (UACR) data, and 5829 (59%) had both measures available. The distribution by eGFR (>89, 60–89, 30–59, <30 ml/min/1.73m²) was 35%, 44%, 18% and 3%, respectively, and by UACR (<30, 30–300, >300 mg/g) 67%, 25% and 8%, respectively. By KDIGO risk group (low, moderate, high, very high), CVD prevalence was 29%, 44%, 53% and 59%, respectively. Use of GLA decreased with increasing CKD except for insulin which increased. Use of renin angiotensin aldosterone system inhibitors was 49–72% across risk groups (Table).

Conclusion

This post hoc CAPTURE analysis demonstrated a positive association between CVD prevalence and CKD risk. CVD medications with proven CVD benefits, including GLA, were underused.

Funding

• Commercial Support –